Clinical data and financing reduce near-term dilution risk and support regulatory milestones. Watch for ASCO presentation (May 29-Jun 2) and FDA filing updates in coming quarters.
Price Chart
Executive Summary
Cellectar Biosciences reported Q1 2026 EPS of -$1.33, beating the -$1.89 consensus, but remains pre-revenue. The key catalysts are positive 12-month follow-up data for iopofosine I 131 in Waldenström Macroglobulinemia and a financing of up to $140M to support accelerated approval and a Phase 3 confirmatory trial.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$1.33 vs consensus -$1.89 (beat 29.6%)
- Positive 12-month follow-up data from CLOVER WaM Phase 2b: 61.8% major response rate, median DOR 17.8 months
- Financing of up to $140M (approx. $35M upfront, $105M milestone-based) led by Nantahala Capital
- Cash $8.3M at March 31, 2026, plus ~$31M net from May 2026 offering; runway into Q2 2027
- Selected for ASCO 2026 presentation; advancing toward accelerated FDA filing and Phase 3 confirmatory study
Financial Impact
EPS beat of 29.6% on consensus -$1.89; net loss improved to $5.7M from $6.6M YoY
Risk Factors
- Clinical trial risks for iopofosine and CLR 125
- Potential dilution from milestone-based warrants
- Cash burn with no revenue; reliance on further financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294782 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers